2024 World Conference on Lung Cancer (WCLC) - Posters-P1.12B.05 Patient and Oncologist Preferences for ALK+ Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments

Pdf Summary

The document presents a study focused on evaluating the preferences of patients and oncologists in the US regarding attributes of ALK-positive advanced non-small cell lung cancer (NSCLC) treatments using tyrosine kinase inhibitors (TKIs). The study employed a discrete choice experiment (DCE) involving 151 patients and 150 board-certified oncologists, utilizing an online preference survey to discern the trade-offs participants were willing to make between treatment benefits and risks.<br /><br />Key findings from the subgroup analysis indicate that previous experiences with tyrosine kinase inhibitors (TKIs), age, and treatment lines influenced the importance patients placed on preventing brain metastasis progression. Younger patients and those on second-line treatments prioritized halting the development of brain metastases. Oncologists emphasized the risks of central nervous system adverse events when treating more than five patients a month, though these differences were not present when comparing academic and non-academic oncologists for these aspects.<br /><br />The results revealed significant disparities in the importance attributed to various treatment attributes between patients and oncologists. Patients prioritized preventing brain metastasis progression, whereas oncologists focused on enhancing three-year progression-free survival (PFS). Both groups valued efficacy over the risks of treatment, being willing to accept certain risks for treatment benefit improvements.<br /><br />This research, one of the first quantitative surveys addressing next-generation ALK TKI treatments specifically, underscores the necessity for shared decision-making in developing treatment plans for ALK-positive advanced NSCLC. Despite the insightful findings, the study acknowledges limitations regarding the representativeness of participants and the hypothetical nature of treatment preference scenarios.<br /><br />The study was sponsored by Pfizer, Inc., and highlights the potential for more personalized and effective treatment strategies in ALK-positive NSCLC by aligning treatment choices with patient and oncologist preferences.

Asset Subtitle

Hannah Le

Meta Tag

Speaker Hannah Le

Topic Metastatic NSCLC – Targeted Therapy

Keywords

ALK-positive NSCLC

tyrosine kinase inhibitors

patient preferences

oncologist preferences

discrete choice experiment

brain metastasis progression

treatment attributes

progression-free survival

shared decision-making

personalized treatment